Click here for slides on this topic


Roux-en-y

 A type of bariatric, or wight-loss, surgery that involves re-secting and re-routing the small intestines to a stomach pouch. 

 


The following content matched the glossary term: Roux-en-y

Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications

Top

Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-2304.

Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes

Top

Schauer PR, Bhatt DL, Kirwan JP, et al; for the STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes–3-year outcomes. N Engl J Med. 2014. doi: 10.1056/NEJMoa1401329.

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia

Top

Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia. JAMA. 2013;309(21):2240-2249.

Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes

Top

Kashyap SR, Bhatt DL, Wolski, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175-2182.

Clinical Insights in Diabetes Newsletter November 2012

Top

Clinical Insights® in Diabetes Newsletter November 2012.

Statins and diabetes, Roux-en-Y for type 2 diabetes and obesity, sitagliptin or liraglutide for type 2 diabetes treatment, obesity and mortality, and DPP-4 inhibitors and cardiovascular disease.

Health benefits of gastric bypass surgery after 6 years

Top

Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308(11):1122-1131. This prospective study by Adams and colleagues explored the weight loss and cardiometabolic benefits of Roux-en-Y gastric bypass (RYGB) among severely obese patients over 6 years of follow-up.

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity

Top

Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420-1428. The authors of the current prospective study sought to examine the potential benefits of laparoscopic Roux-en-Y gastric bypass (LRYGB) among those with BMI 30-34.9 kg/m2 (class I obesity) and type 2 diabetes.



Slide Library Results

Search Results for: Roux-en-y Slides Found: 43
Bariatric Surgery: Gastrorestrictive Procedures
Gastrorestrictive Surgery: Outcomes
Laparoscopy and Liposuction
Effect of Bariatric Surgery on Acute Insulin Response
Effect of Roux-en-Y Bypass on Treatment of Type 2 Diabetes
Quality of Life After Bariatric Surgery: Nottingham Health Profile (NHP)
Bariatric Surgery: Conclusions
STAMPEDE: Design
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Long-term Change in BMI After Roux-en-Y Gastric Bypass
Late Complications of Roux-en-Y Gastric Bypass
Bariatric Surgery for Obesity
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Glycemic Control Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Operative Safety, Waist Circumference
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Additional Parameters
RYGB Surgery: Long-Term Health-Related Outcomes Design
RYGB Surgery: Weight Change, Maintenance Over 6 Years
RYGB Surgery: Diabetes Remission at 6 Years
RYGB Surgery: Diabetes Incidence at 6 Years
RYGB Surgery: Incidence of Hypertension, Dyslipidemia Values at 6 Years
RYGB Surgery: Remission of Hypertension, Dyslipidemia Values at 6 Years
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
Diabetes Surgery Study: Design
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Reduction in Truncal Fat with Gastric Bypass Vs Sleeve Gastrectomy
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
STAMPEDE Metabolic Substudy: Design
LABS-2: 3-Yr Weight Loss After Bariatric Surgery
LABS-2: 3-Yr Mortality After Bariatric Surgery
LABS-2: 3-Yr Remission & Incidence of Cardiometabolic Outcomes After Bariatric Surgery
Teen-LABS: Rates of Complications 30 Days After Bariatric Surgery
AHA/ACC/TOS Obesity Guidelines: Bariatric Surgery Complications
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
AMOS Study Bariatric Surgery for Adolescents With Severe Obesity | NDEI
Bariatric Surgery & Long-Term Survival in Veterans Severe Obesity | NDEI
Safety Bariatric Surgery for BMI <35 at 1 Year
RYGB Vs Sleeve Gastrectomy for Weight Loss & Glycemic Control ENDO2015 | NDEI
Bariatric Metabolic Surgery for Weight Loss Type 2 Diabetes AHA ADA | NDEI
Study Examines Overall Safety of Bariatric (Metabolic/Diabetes) Surgery
Metabolic Surgery Procedures for Treating Type 2 Diabetes Guidelines | NDEI